Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer

• Published in: Biochemical and biophysical research communications Vol. 477; no. 4; pp. 937 - 944
• Main Authors: Rastogi, Ichwaku, Rajanna, Supriya, Webb, Andrew, Chhabra, Gagan, Foster, Brad, Webb, Brian, Puri, Neelu
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 02.09.2016
• Subjects: 60 APPLIED LIFE SCIENCES; Antineoplastic Agents - administration & dosage; cadherins; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - pathology; cell adhesion; Cell Line, Tumor; CELL PROLIFERATION; DIAGNOSIS; Drug Resistance, Neoplasm; DRUGS; EMT; Epithelial-Mesenchymal Transition - drug effects; epithelium; GENES; Humans; lung neoplasms; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; LUNGS; miR-200a; MOLECULES; MORPHOLOGY; neoplasm cells; NEOPLASMS; NSCLC; PATIENTS; people; Protein Kinase Inhibitors - administration & dosage; protein synthesis; Protein-Tyrosine Kinases - antagonists & inhibitors; Receptor Protein-Tyrosine Kinases - metabolism; Receptor, Epidermal Growth Factor - metabolism; RECEPTORS; repressor proteins; SENSITIVITY; small interfering RNA; therapeutics; THERAPY; TKI resistance; Treatment Outcome; TYROSINE; vimentin; Zeb-1; β-Catenin; β-Catenin; Zeb-1; TKI resistance; β-Catenin; miR-200a; NSCLC; EMT

According to currently available estimates from Cancer Research UK, 14.1 million new lung cancer cases were diagnosed and a staggering 8.2 million people worldwide died from lung cancer in 2012. EGFR and c-Met are two tyrosine kinase receptors most commonly overexpressed or mutated in Non-small Cell...